Read about our strategic alliances aimed at giving our clients an end to end service using the best experts in the business…
In November 2014, we launched a strategic alliance with Maryland based, Xceleron to assist drug developers with improved efficiency during clinical development.
The partnership extends our ROADMAP to Clinical Trials enabling technologies platform, with Xceleron’s expertise in the use of Accelerator Mass Spectrometry (AMS) analytical technology in pharmaceutical product applications added to the platform to support companies with the rapid development of both standard and complex drug products. The partnership also assists drug developers in:
• Improving the quality and accuracy of clinical data based on drug disposition
• Supporting early proof of concept studies
Established in 1998, speciality analytical company Xceleron has a global client base and primarily designs preclinical and clinical investigations around the unique analytical features of AMS to improve R&D efficiency. For more information about Xceleron visit www.xceleron.com.
In July 2014, we agreed a collaboration with fellow Nottingham-based company XenoGesis aimed at supporting pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.
Supporting our development services, XenoGesis brings expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give our clients a smarter route into formulation development and a better understanding of a compound’s bioavailability. The partnership assists drug developers in:
• The initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies
• Supporting lead candidates, which have solubility issues during formulation development
XenoGesis, is a contract research organisation (CRO) that specialises in expert DMPK/ADME laboratory services and interpretation and drug discovery consultancy. The team has significant experience and a track record of delivering candidate drugs to man from their careers at AstraZeneca R&D Charnwood. XenoGesis supports the drug discovery activities of biotechnology and pharmaceutical companies and academic units. For more information about XenoGesis visit www.xenogesis.com.
In 2012, we struck an strategic alliance with Onyx Scientific based in North East England. The partnership was devised to enable our two contract research and manufacturing organisations to deliver end-to-end services from initial drug discovery through to early and late phase manufacturing.
Complementing our expertise in advanced characterisation of pharmaceutical and biological materials and formulation development, the team at Onyx Scientific help us to provide a more comprehensive service to clients by offering:
• Custom synthesis
• Lead optimisation
• Process development
• Solid state chemistry
While Juniper Pharma Services has specialist knowledge on developing challenging molecules, Onyx Scientific is the expert when it comes to dealing with complex chemistry. For more information about Onyx Scientific visit www.onyxipca.com.
To find out more about how we and our partners can help you, get in touch today.